Bio-Techne shareholders have approved the $11.3 billion acquisition by Merck KGaA of Darmstadt, Germany, clearing a key procedural milestone as the deal moves toward a close expected by late 2026 or early 2027.
Media partner
M&A · LIFE SCIENCE TOOLS M&A · SEPTEMBER 26, 2026 · GLOBAL
Shareholder approval, secured at a special meeting of Bio-Techne Corporation stockholders on 23 September 2026, has cleared the most visible procedural gate in Merck KGaA’s $11.3 billion bid for the Minneapolis-based life science tools and diagnostics supplier. The merger proposal received 121.9 million votes in favour and 1.2 million against, according to Bio-Techne’s Form 8-K filing. With the U.S. waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) having expired on 18 September 2026, the transaction’s critical path now runs through the remaining required regulatory approvals ahead of a close that Bio-Techne expects by late 2026 or early 2027.
The deal, announced on 25 June 2026 at $73 per share in cash — a 24% premium to Bio-Techne’s closing price the day before, according to Reuters, and a 36% premium to its one-month volume-weighted average price, according to Merck KGaA — was Merck KGaA’s largest acquisition since its 2014 purchase of Sigma-Aldrich, according to Reuters. Merck KGaA expects annual cost synergies of approximately €140 million, anticipated to be fully realised by the third year after closing, per the company’s announcement.
What the Regulatory Clock Now Governs
The U.S. antitrust gate has already been passed: the HSR waiting period expired at 11:59 p.m. Eastern Time on 18 September 2026, per Bio-Techne. Closing remains subject to customary conditions, including receipt of the remaining required regulatory approvals. Reuters reported in June that some analysts did not expect significant regulatory hurdles. A contract announced is not a contract executed.
Bio-Techne’s most recent quarterly results, for the fourth quarter of fiscal 2026, showed revenue of $321.2 million, above analysts’ expectations of $314.7 million, according to Reuters. Its Protein Sciences segment — which develops and manufactures biological compounds used for research, diagnostics, and cell and gene therapy development — posted revenue of $231.2 million in that quarter, a 2.1% increase year-over-year. The Diagnostics and Spatial Biology segment, which provides spatial biology products, diagnostic tests, and laboratory quality-control products, contributed $90.1 million, up 0.5%. Chief Executive Officer Kim Kelderman described the quarter as reflecting ‘improved performance and solid execution across the business,’ per Reuters.
That sequential recovery matters for the deal’s strategic logic. Earlier in fiscal 2026, Bio-Techne missed third-quarter revenue estimates — posting $311.4 million — as cuts to U.S. academic funding weighed on demand, according to Reuters. Kelderman acknowledged at the time that while biotech funding remained healthy, it had ‘not yet translated into broad-based demand across our portfolio.’ The fourth-quarter rebound suggests the academic-funding headwind may be stabilising, though the company has not provided forward guidance that would confirm that trajectory.
The Activist Backdrop and the Standalone Question
The shareholder vote did not occur in a vacuum. Ananym Capital Management, an activist investor, had built a stake in Bio-Techne and in June 2026 pushed the board to conduct a strategic review that would include a potential sale, according to Bloomberg. In its letter, Ananym said Bio-Techne’s organic growth has lagged peers, as reported by Investing.com. The lopsided vote suggests the sale found broad support among shareholders, who at the same time rejected, in a separate non-binding vote, the merger-related executive compensation proposal by 96.4 million votes to 25.9 million, per the Form 8-K.
Merck KGaA’s appetite for acquisitions predates the Bio-Techne deal. In April 2025, the German group agreed to acquire SpringWorks Therapeutics for $3.9 billion, handing it two approved drugs for rare tumors, according to BioPharma Dive. The Bio-Techne transaction, at $11.3 billion including debt, is substantially larger and oriented toward tools and infrastructure rather than approved therapeutics — a different strategic register that reflects Merck KGaA’s stated ambition to position itself as a ‘globally diversified, innovation and technology powerhouse,’ in the words of then-Chief Executive Officer Belén Garijo, as quoted by BioPharma Dive at the time of the SpringWorks announcement.
Merck KGaA’s own financial trajectory reinforces the rationale. In August 2026, the group raised its full-year adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) guidance to between €5.9 billion and €6.3 billion, up from a prior range of €5.7 billion to €6.1 billion, citing strong demand for semiconductor materials and drug production supplies, according to Reuters. Quarterly adjusted EBITDA rose 9.4% to €1.60 billion, above the analyst consensus of €1.53 billion, according to Reuters.
The principal friction point between announcement and close is not commercial but procedural. With the HSR waiting period expired, timing now depends on the remaining required regulatory approvals. Merck KGaA’s late-2026-to-early-2027 closing window is a company projection, not a regulatory commitment.
On the Latin American regulatory pathway: no filing or approval by Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), or Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) has been reported in connection with this transaction. A corporate acquisition of this type would not typically require product-level regulatory filings in those jurisdictions, though any post-close restructuring of local distribution or manufacturing arrangements could trigger separate national review processes — a mechanism the companies have not addressed publicly.
What to Watch
- Receipt of the remaining required regulatory approvals, following expiry of the U.S. HSR waiting period on 18 September 2026
- Whether Merck KGaA narrows or reaffirms the late-2026-to-early-2027 closing window as regulatory review progresses
- Post-close integration disclosures, particularly how the €140 million synergy target is allocated between cost reduction and revenue reinvestment in the Protein Sciences and Diagnostics and Spatial Biology segments
THE HEALTHSIGNALS BRIEF
Track the ANVISA and COFEPRIS filings we flag here — every two weeks, in one PDF.
You're in. The next Brief lands in your inbox.
The deeper tension in this transaction is between the tools business’s exposure to public research funding — a headwind Bio-Techne experienced acutely in the third quarter of fiscal 2026 — and Merck KGaA’s thesis that large-pharma demand for bioprocessing and research reagents will structurally offset that volatility. The synergy figure addresses costs, not revenue mix; whether the combined entity rebalances Bio-Techne’s customer base away from U.S. academic institutions is a strategic question the available record does not yet answer.
Bio-Techne Acquisition by Merck KGaA — Key Terms
Enterprise Value
$11.3B
Deal value
Per-Share Price
$73
24% premium to pre-offer close
Expected Close
Late 2026 or Early 2027
Company guidance
Year 3 Cost Synergies
~€140M
Annual run-rate target
Bio-Techne Fourth-Quarter Fiscal 2026 Performance: Total revenue $321.2M (vs. consensus $314.7M); Protein Sciences segment $231.2M (+2.1% year over year); Diagnostics and Spatial Biology $90.1M (+0.5% year over year).
Sources: Merck KGaA and Bio-Techne announcement (deal terms, synergies and close timing, as of 2026-06-25); Reuters (premium, as of 2026-06-25; fourth-quarter fiscal 2026 results, as of 2026-08-12).
Why this is relevant
Patients
The combination of Merck KGaA’s bioprocessing infrastructure with Bio-Techne’s protein sciences and spatial biology portfolio may be associated with broader availability of research tools that underpin cell and gene therapy development, though no direct patient-access mechanism or timeline has been announced.
Industry
Merck KGaA expects approximately €140 million in annual cost synergies by the third year after closing, a figure that suggests meaningful restructuring of Bio-Techne’s operations; mid-tier reagent and diagnostics suppliers may face increased competitive pressure from the combined entity, though the precise integration plan has not been disclosed.
Payers
This transaction is a corporate acquisition of life science tools and diagnostics infrastructure rather than a drug or device approval; no direct reimbursement, formulary, or coverage decision is implicated by the available record, and no payer-facing pricing change has been announced.
Litigation
The U.S. HSR waiting period expired on 18 September 2026; closing remains subject to the remaining required regulatory approvals and customary conditions ahead of the projected late-2026-to-early-2027 close. No legal disputes have been disclosed in the available record.
Sources: Bio-Techne (23 September 2026); Bio-Techne Form 8-K vote results; Merck KGaA and Bio-Techne (25 June 2026); Bio-Techne fourth-quarter fiscal 2026 results; Bio-Techne third-quarter fiscal 2026 results; Reuters via Euronext (6 August 2026); BioPharma Dive (28 April 2025); Bloomberg (15 June 2026).
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.
Your subscription could not be validated.
You have successfully subscribed.
